Home Conference: What to Expect

Conference: What to Expect

What to Expect at ESMO 2022: Phase 1 Data of Zanidatamab Zovodotin (ZW49)...

Prelinimary results a Phase 1 study of zanidatamab zovodotin (ZW49), an investigational novel bispecific HER2 targeted antibody-drug conjugate being...

ASH 2020: Potential of Belantamab Mafodotin in Combination Standard Therapies in Treatment of Multiple...

Multiple myeloma is the second most common hematological malignancy in the United States and is generally considered treatable, but...

What to Expect at SABCS 2020: New Data for HER2 and HER3 Directed DXd...

New research data for trastuzumab deruxtecan (fam-trastuzumab deruxtecan-nxki; Enhertu®; Daiichi Sankyo) and patritumab deruxtecan (U3-1402; HER3-DXd), two DXd antibody-drug...

Seagen Presents Broad Portfolio of Innovative Immuno-Oncology Data – Featuring Sugar-Engineered Antibodies

During the upcoming 35th annual meeting of the Society for Immunotherapy of Cancer’s (SITC) being held November 9-14, 2020,...

X